News · 26 weeks53+300%
2026-03-012026-08-23
Mix1590d
- Insider7(47%)
- Other5(33%)
- SEC Filings2(13%)
- Earnings1(7%)
Latest news
25 items- INSIDERPresident & CEO Mackin James P sold $2,026,850 worth of shares (70,000 units at $28.95), decreasing direct ownership by 7% to 877,275 units (SEC Form 4)4 - ARTIVION, INC. (0000784199) (Issuer)
- INSIDERSVP, Regulatory and Quality Green Andrew M sold $17,586 worth of shares (616 units at $28.55), decreasing direct ownership by 1% to 59,643 units (SEC Form 4) to satisfy withholding tax4 - ARTIVION, INC. (0000784199) (Issuer)
- INSIDEREVP, COO, CFO & Treasurer Berry Lance A sold $20,413 worth of shares (715 units at $28.55), decreasing direct ownership by 0.34% to 210,112 units (SEC Form 4) (tax liability)4 - ARTIVION, INC. (0000784199) (Issuer)
- INSIDERSVP, General Counsel Holloway Jean F sold $27,835 worth of shares (977 units at $28.49), decreasing direct ownership by 0.53% to 184,118 units (SEC Form 4)4 - ARTIVION, INC. (0000784199) (Issuer)
- SECSEC Form 10-Q filed by Artivion Inc.10-Q - ARTIVION, INC. (0000784199) (Filer)
- SECArtivion Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ARTIVION, INC. (0000784199) (Filer)
- PRArtivion Reports Second Quarter 2026 Financial ResultsSecond Quarter & Recent Business Highlights: Achieved revenue of $125.8 million in the second quarter of 2026 versus $113.0 million in the second quarter of 2025, an increase of 11% on a GAAP basis and 9% on a non-GAAP constant currency basis Net loss for the second quarter of 2026 was $(13.5) million, or $(0.28) per fully diluted share, and non-GAAP net income was $6.3 million, or $0.13 per fully diluted shareAdjusted EBITDA increased 7% to $26.4 million in the second quarter of 2026 compared to $24.8 million in the second quarter of 2025Announced U.S. FDA PMA Approval of the AMDS Hybrid ProsthesisCompleted acquisition of Endospan Ltd.ATLANTA, Aug. 6, 2026 /PRNewswire/ -- Artivion, Inc. (NY
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Artivion Inc.SCHEDULE 13G/A - ARTIVION, INC. (0000784199) (Subject)
- PRArtivion to Participate in Upcoming Investor ConferencesATLANTA, July 28, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences. Artivion's management team will present at the upcoming Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at the InterContinental Boston Hotel. The Company's presentation is scheduled to begin at 9:30 a.m. ET. A live webcast can be accessed through Artivion's website, www.artivion.com, on the Investors page. An archived copy of the webcast will be available for 90 days on the same web
- PRArtivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial ResultsATLANTA, July 23, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2026 financial results will be released on Thursday, August 6, 2026, after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question-and-answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of Artivion. To listen to the live teleconference, please dial 201-689-8261 a few minutes prior to 4:30 p.m. ET. The teleconference replay
- PRArtivion Announces U.S. FDA Approval of the AMDS Hybrid ProsthesisATLANTA, June 29, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration (FDA) has approved the premarket approval application (PMA) for the AMDS Hybrid Prosthesis ("AMDS"). The approval covers acute Debakey Type I aortic dissections with either clinical or radiographic malperfusion, which the Company estimates to be approximately 60% of all Debakey Type I aortic dissections. Given this approval, hospitals will no longer be required to obtain institutional review board (IRB) approval in order to implant AMDS in their institutions, a requirement associated with the Hu
- INSIDERSVP, Regulatory and Quality Green Andrew M exercised 44,001 shares at a strike of $13.39 and sold $910,739 worth of shares (44,001 units at $20.70) as part of a pre-agreed trading plan (SEC Form 4)4 - ARTIVION, INC. (0000784199) (Issuer)
- PRArtivion to Participate in the 2026 Truist Securities MedTech ConferenceATLANTA, June 10, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate at the upcoming 2026 Truist Securities MedTech Conference on Tuesday, June 16, 2026, at the Boston Harbor Hotel. The Company's fireside chat is scheduled to begin at 1:00 p.m. ET on Tuesday, June 16, 2026. A live webcast can be accessed through Artivion's website, www.artivion.com, on the Investors page. An archived copy of the webcast will be available for 90 days on the same website.About Artivion, Inc.Headquartered in suburban Atlanta, Georgia, A
- INSIDERNew insider Green Andrew M claimed ownership of 60,259 shares (SEC Form 3)3 - ARTIVION, INC. (0000784199) (Issuer)
- INSIDERDirector Semedo Anthony B. disposed of 6,325 shares and acquired 6,325 shares, decreasing direct ownership by 13% to 40,635 units (SEC Form 4)4 - ARTIVION, INC. (0000784199) (Issuer)
- SECSEC Form SD filed by Artivion Inc.SD - ARTIVION, INC. (0000784199) (Filer)
- INSIDERAmendment: Director Borgstrom Marna P was granted 7,576 shares, increasing direct ownership by 15% to 56,664 units (SEC Form 4)4/A - ARTIVION, INC. (0000784199) (Issuer)
- INSIDERDirector Semedo Anthony B. was granted 7,576 shares, increasing direct ownership by 19% to 46,960 units (SEC Form 4)4 - ARTIVION, INC. (0000784199) (Issuer)
- INSIDERDirector Salveson Jon W was granted 7,576 shares, increasing direct ownership by 6% to 137,416 units (SEC Form 4)4 - ARTIVION, INC. (0000784199) (Issuer)
- INSIDERDirector Hoff Elizabeth A was granted 7,576 shares, increasing direct ownership by 28% to 34,765 units (SEC Form 4)4 - ARTIVION, INC. (0000784199) (Issuer)
- INSIDERDirector Burbank Jeffrey H was granted 7,576 shares, increasing direct ownership by 14% to 61,372 units (SEC Form 4)4 - ARTIVION, INC. (0000784199) (Issuer)
- INSIDERDirector Bullock James was granted 7,576 shares, increasing direct ownership by 11% to 76,223 units (SEC Form 4)4 - ARTIVION, INC. (0000784199) (Issuer)
- INSIDERDirector Bevevino Daniel J was granted 7,576 shares, increasing direct ownership by 5% to 157,637 units (SEC Form 4)4 - ARTIVION, INC. (0000784199) (Issuer)
- INSIDERDirector Ackerman Thomas F was granted 7,576 shares, increasing direct ownership by 5% to 157,472 units (SEC Form 4)4 - ARTIVION, INC. (0000784199) (Issuer)
- INSIDERDirector Borgstrom Marna P was granted 7,850 shares, increasing direct ownership by 16% to 56,938 units (SEC Form 4)4 - ARTIVION, INC. (0000784199) (Issuer)
AORT FAQ
6 questionsWhat does Artivion Inc. do?
Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G...Where does AORT stock trade?
Artivion Inc. (AORT) is listed on NYSE.What sector and industry is AORT in?
Artivion Inc. operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about AORT?
Artivion Inc. has had 8 recent analyst actions on file. The most recent action was from Ladenburg Thalmann: Buy with a $4200.00 price target on 2026-04-10. Recent price targets range from $2800.00 to $4200.00.What companies are similar to AORT?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare AORT side-by-side with any of them on Quantisnow.How can I track AORT on Quantisnow?
Quantisnow aggregates Artivion Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AORT to receive live email and push alerts on every new disclosure.